Pacific Biosciences of California PACB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 37.5%+8.9pp | 28.6%+3.2pp | 25.4%+4.0pp | 21.4%+5.2pp | 16.2%-8.0pp | |
| Operating margin | -83.3%+263pp | -346.2%+84.5pp | -430.6%+11.9pp | -442.6%+96.9pp | -539.4%-231pp | |
| Net margin | -80.3%+261pp | -341.5%-14.1pp | -327.3%+11.4pp | -338.7%+94.6pp | -433.3%-231pp | |
| EBITDA margin | -74.5%+32.7pp | -107.1%+72.3pp | -179.4%+9.5pp | -188.9%+86.3pp | -275.2%+6.0pp | |
| Free cash flow margin | -72.6%-1.4pp | -71.2%+10.5pp | -81.7%+15.9pp | -97.6%+19.3pp | -116.9%+20.9pp | |
| Returns | ||||||
| Return on equity | -273.6%-60.1pp | -213.5%-6.6pp | -206.9%-16.1pp | -190.8%-12.6pp | -178.3%-127pp | |
| Return on assets | -15.6%+37.8pp | -53.4%-8.5pp | -44.9%+0.4pp | -45.3%+6.9pp | -52.2%-31.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Inventory turnover | 1.2×-0.2× | 1.4×-0.1× | 1.5×0.0× | 1.6×-0.1× | 1.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.7×+0.5× | 5.1×-1.1× | 6.2×-0.7× | 6.9×+0.2× | 6.7×-0.8× | |
| Quick ratio | 4.4×+0.4× | 4×-0.9× | 4.9×-0.5× | 5.5×0.0× | 5.4×-0.8× | |
| Cash ratio | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 25.1×+14.4× | 10.7×+9.1× | 1.5×+0.7× | 0.9×+0.3× | 0.6×+0.5× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -19.2×+60.5× | -79.6×+3.9× | -83.5×-12.8× | -70.7×+0.3× | -71×-35.6× | |
| Per Share | ||||||
| Book value per share | $0.01-56.7% | $0.02-85.2% | $0.12-41.4% | $0.20-33.6% | $0.31-82.4% | |
| Valuation | ||||||
| Market capitalization | $496.96M+30.4% | $564.57M+46.8% | $384.47M+6.8% | $360.1M+2.5% | $351.47M-34.7% | |
| Enterprise value | $498.38M+33.5% | $556.35M+46.0% | $381.1M+7.0% | $356.25M+3.7% | $343.63M-32.1% | |
| Price / sales | 3.1×+0.6× | 3.5×+1.0× | 2.5×+0.2× | 2.3×0.0× | 2.3×-1.2× | |
| Price / book | 210×+206× | 105.5×+94.9× | 10.7×+4.8× | 5.9×+2.0× | 3.8×+2.8× | |
| EV / sales | 3.1×+0.7× | 3.5×+1.0× | 2.5×+0.2× | 2.3×0.0× | 2.3×-1.0× | |
| Free cash flow yield | -23.4%+23.4pp | -20.2%+12.7pp | -32.8%+9.5pp | -42.3%+8.4pp | -50.7%-11.3pp | |
| Earnings yield | -25.9%+147pp | -96.8%+34.8pp | -131.6%+15.2pp | -146.8%+41.0pp | -187.8%-130pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacific Biosciences of California's profit margins?
- Pacific Biosciences of California (PACB) runs a 37.5% gross margin and a -83.3% operating margin, with a -80.3% net margin.
- Where do Pacific Biosciences of California's ratios come from?
- Every ratio is computed from Pacific Biosciences of California's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
